1. Home
  2. VIVO vs BTAI Comparison

VIVO vs BTAI Comparison

Compare VIVO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VIVO

VivoPower PLC Ordinary Shares

N/A

Current Price

$4.75

Market Cap

37.5M

Sector

Utilities

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIVO
BTAI
Founded
2014
2017
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.5M
35.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VIVO
BTAI
Price
$4.75
$1.16
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
2.1M
636.3K
Earning Date
05-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$1.01
52 Week High
$6.86
$8.08

Technical Indicators

Market Signals
Indicator
VIVO
BTAI
Relative Strength Index (RSI) 50.58 49.65
Support Level $4.24 $1.05
Resistance Level $5.25 $1.26
Average True Range (ATR) 0.80 0.09
MACD -0.18 -0.01
Stochastic Oscillator 20.44 30.14

Price Performance

Historical Comparison
VIVO
BTAI

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: